Work

The Economics of Reproducibility in Preclinical Research

Year: 2015

Type: article

Abstract: Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.

Source: PLoS Biology

DOI: 10.1371/journal.pbio.1002165

Authors: Leonard P. Freedman, Iain M. Cockburn, Timothy S. Simcoe

Institutions: Global Biological Standards Institute, Boston University, Council of Economic Advisers

Language: English

Topic: Animal testing and alternatives

Subfield: Small Animals

Field: Veterinary

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,500